2025年4月4日 星期五
首页        期刊介绍        编委会        投稿指南        期刊订阅        广告合作        联系我们        English
河北医学  2019, Vol. 25 Issue (8): 1280-1283    DOI: 10.3969/j.issn.1006-6233.2019.08.013
  论著 本期目录 | 过刊浏览 | 高级检索 |
单磷酸阿糖腺苷联合普米克令舒对毛细支气管炎患儿的疗效及对血清LTE4 MCP-1 INF-γ的影响
晁玉瑾
中国人民解放军联勤保障部队第九六O医院儿科, 山东 济南 250031
Effects of Adenosine Monophosphate combined with Pulmicort Respules on Serum LTE4, MCP-1 and INF-gamma in Children with Bronchiolitis
CHAO Yujin
The 960th Hospital of PLA Joint Logistice Support Force, Shandong Ji'nan 250031, China
全文: PDF (1235 KB)   HTML (1 KB) 
输出: BibTeX | EndNote (RIS)      
摘要 目的:探讨单磷酸阿糖腺苷联合普米克令舒对毛细支气管炎患儿的疗效及对血清白三烯E4(LTE4)、单核细胞趋化蛋白-1(MCP-1)、干扰素-γ(INF-γ)的影响。方法:选择2015年2月至2017年2月于我院进行治疗的90例毛细支气管炎患儿进行研究,随机分为观察组(n=48)和对照组(n=42)。观察组采用单磷酸阿糖腺苷联合普米克令舒进行治疗。对照组采用普米克令舒治疗。比较两组患者的临床疗效、血清LTE4、MCP-1、INF-γ、肿瘤坏死因子α(TNF-α)、白细胞介素-6(IL-6)、白细胞介素-8(IL-8)、临床症状消失时间及两组患儿不良反应发生情况。结果:观察组患儿治疗后有效率为95.83%,显著高于对照组的80.95%(P<0.05);治疗后,两组患儿血清LTE4、MCP-1、INF-γ水平均显著改善(P<0.05);且观察组患儿血清LTE4、MCP-1水平均低于对照组,INF-γ水平显著高于对照组(P<0.05);治疗后,两组患儿血清TNF-α、IL-6、IL-8水平均显著改善(P<0.05);且观察组患儿血清TNF-α、IL-6、IL-8水平均低于对照组(P<0.05);观察组患儿退热时间、湿啰音消失时间、喘息消失时间、咳嗽消失时间及住院时间明显低于对照组(P<0.05);两组患儿皮疹、恶心腹泻、血管性水肿总发生率分别为8.33%、16.67%,比较差异无统计学意义(P>0.05)。结论:单磷酸阿糖腺苷联合普米克令舒治疗毛细支气管炎患儿的疗效较高,可有效改善患者血清LTE4、MCP-1、INF-γ水平,不良反应较少,且患儿基本可以耐受,值得推广应用。
服务
把本文推荐给朋友
加入我的书架
加入引用管理器
E-mail Alert
RSS
作者相关文章
晁玉瑾
关键词 毛细支气管炎单磷酸阿糖腺苷普米克令舒白三烯E4单核细胞趋化蛋白-1干扰素-γ    
AbstractObjective: To study Curative efficacy of Vidarabine monophosphate combined with primeresch in treatment of Children with bronchiolitis and its effectson serum Leukotriene E4 (LTE4), monocyte chemokinin-1 (McP-1), interferon-gamma (inf-gamma). Methods: 90 children with bronchiolitis treated in our hospital from February 2015 to February 2017 was conducted, they were randomly divided into observation group (n=48) and control group (n=42). The observation group was treated with adenosine monophosphate combined with pulmicort respules. The control group was treated with pulmicort respules. The clinical efficacy, serum LTE4, McP-1, inf-gamma, TNF- alpha, interleukin-6 (il-6), interleukin-8 (il-8), time of disappearance of clinical symptoms and adverse reactions in the two groups were compared. Results: The effective rate of the observation group was 95.83%, significantly higher than that of the control group (80.95%, P<0.05). After treatment, serum LTE4, McP-1 and inf-gamma levels were significantly improved in the two groups (P<0.05). Serum LTE4 and McP-1 levels in the observation group were lower than those in the control group, and inf-gamma levels were significantly higher than those in the control group (P<0.05). After treatment, serum tnf-alpha, il-6 and il-8 levels were significantly improved in both groups (P<0.05). Serum tnf-alpha, il-6 and il-8 levels in the observation group were lower than those in the control group (P<0.05). The time of antipyretic, time of disappearance of moist rale, time of disappearance of wheezing, time of disappearance of cough and time of hospitalization in the observation group was significantly lower than that in the control group (P<0.05). The total incidence of rash, nausea, diarrhea and angioedema in the two groups was 8.33% and 16.67%, respectively, with no statistically significant difference (P>0.05). Conclusion: The efficacy of adenosine monophosphate combined with pramikacin in the treatment of bronchiolitis in children is relatively high, which can effectively improve the serum LTE4, McP-1 and inf-gamma levels in patients with less adverse reactions, and the children are basically tolerable and worthy of popularization and application.
Key wordsBronchitis    Adenosine monophosphate    Pulmicort respules    Leukotriene E4    Monocyte chemokinin-1    Interferon gamma
    
基金资助:山东省自然科学基金项目,(编号:ZR2014HL001)
引用本文:   
晁玉瑾. 单磷酸阿糖腺苷联合普米克令舒对毛细支气管炎患儿的疗效及对血清LTE4 MCP-1 INF-γ的影响[J]. 河北医学, 2019, 25(8): 1280-1283.
CHAO Yujin. Effects of Adenosine Monophosphate combined with Pulmicort Respules on Serum LTE4, MCP-1 and INF-gamma in Children with Bronchiolitis. HeBei Med, 2019, 25(8): 1280-1283.
链接本文:  
http://www.hbyxzzs.cn/CN/10.3969/j.issn.1006-6233.2019.08.013     或     http://www.hbyxzzs.cn/CN/Y2019/V25/I8/1280
冀ICP备2025106803号    冀公网安备13080202000786号
版权所有 © 2016 《河北医学》杂志社
本系统由北京玛格泰克科技发展有限公司设计开发